How has been the historical performance of Nucleus Soft.?
Nucleus Soft has shown steady growth in net sales, increasing from 484.03 Cr in Mar'19 to 832.25 Cr in Mar'25, despite fluctuations in profit margins and cash flow. Total assets also grew significantly, from 757.89 Cr in Mar'20 to 1,152.95 Cr in Mar'25.
Answer:The historical performance of Nucleus Soft shows a steady growth in net sales and profit over the years, with some fluctuations in margins and expenses.Breakdown:
Nucleus Soft's net sales have increased from 484.03 Cr in Mar'19 to 832.25 Cr in Mar'25, indicating a consistent upward trend. Total operating income followed a similar trajectory, reaching 832.25 Cr in Mar'25 from 484.03 Cr in Mar'19. The total expenditure, excluding depreciation, rose from 404.78 Cr in Mar'19 to 663.90 Cr in Mar'25, reflecting increased operational costs. Operating profit, excluding other income, peaked at 220.40 Cr in Mar'24 but fell to 168.35 Cr in Mar'25. Profit before tax also showed growth, reaching 219.05 Cr in Mar'25, although it was lower than the previous year's 255.80 Cr. Profit after tax reached 163.00 Cr in Mar'25, down from 191.60 Cr in Mar'24. The company's total assets grew from 757.89 Cr in Mar'20 to 1,152.95 Cr in Mar'25, while total liabilities increased from 404.78 Cr to 1,152.95 Cr in the same period. Cash flow from operating activities was 150.00 Cr in Mar'25, down from 222.00 Cr in Mar'24, but the closing cash and cash equivalents rose to 50.00 Cr in Mar'25 from 45.00 Cr in Mar'24. Overall, Nucleus Soft has demonstrated significant growth in sales and assets, despite some fluctuations in profit margins and cash flow.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
